Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Neomycin

Alternative Names: neomycin, sofra-tulle, neomicina, cordran n, mycifradin, neo-fradin, neobiotic, casporyn hc, mytrex a, cortisporin, neo-hydeltrasol, lumi-sporyn, neo-cort-dome, statrol, neodecadron, oticair, otocort, otobione, dexacidin, dexasporin, neosporin, neo-polycin, lanabiotic, poly-pred, pediotic, cor-oticin, neosporin g.u. irrigant, mycitracin, neo polycin hc, cortisporin tc, neo polycin
Latest Update: 2025-03-26
Latest Update Note: News Article

Product Description

Neomycin is a medication used in the treatment and management of hepatic coma and perioperative prophylaxis. Neomycin belongs to a group of antibiotics known as aminoglycosides. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK560603/)

Mechanisms of Action: Protein Synthesis Inhibitor,30S Ribosomal Subunit Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Schur Pharmazeutika & KG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Neomycin

Countries in Clinic: France, Romania

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Candidiasis, Vulvovaginal|Vaginosis, Bacterial

Phase 2: Retinitis Pigmentosa

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HORA-PDE6B-001

P2

Unknown Status

Retinitis Pigmentosa

2029-11-07

NNMAIS 01/2021

P3

Unknown Status

Candidiasis, Vulvovaginal|Vaginosis, Bacterial

2026-07-01

Recent News Events

Date

Type

Title

03/26/2025

News Article

 Public Advisory - Health Canada warns about unauthorized health products that may pose serious health risks

12/02/2024

News Article

 Public Advisory - Health Canada warns about unauthorized health products that may pose serious health risks

10/29/2024

News Article

 Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

09/25/2023

News Article

 Global Aminoglycosides Market to Surge to $5.8 Bilion by 2032, Fueled by Infectious Disease Challenges

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions